The Onyx overcomes many of the limitations of CRISPR-based gene editing, giving almost any lab access to genome engineering in bacteria and yeast on a massive scale and has been named a 2020 Top Ten Innovation by The Scientist.
Inscripta’s application note developed in collaboration with Dr. Markus Herrgård from Novo Nordisk details the generation of a ALE-derivated mutations engineered into E coli genome.
Inscripta’s application note details the generation of precision-engineered E. coli populations and analysis of pooled growth selection in the presence of inhibitory compounds
The promise of CRISPR editing will not be realized without meaningful innovation in scalability, efficiency and access.
Gene editing using the MAD7™nuclease has been demonstrated in both E. coli and yeast organisms, and now in mammalian cells.
Here we describe the MAD7 nuclease, a system that targets TTTN PAMs and shows both cutting and editing activity in E. coli and S. cerevisiae.
To address the need for an expanded range of nucleic acid-directed endonucleases, Inscripta™ is developing new classes of RNA-guided…
Poster presentation at 2019 GP‑W & SC2.0 Meeting. The Onyx™ platform developed by Inscripta Inc., dramatically increases the scale of Digital Genome Engineering and simplifies the complex editing workflow for biologists.
Inscripta is committed to responsible, ethical use of the technology we are creating. We have developed and implemented a biosecurity system designed to identify biothreat scenarios and aim to be leaders in ensuring that biosecurity is a priority for the growing genome engineering community.